Quorum Review IRB has been awarded full reaccreditation for another three years by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).
AAHRPP accredits organizations that can demonstrate they provide participant safeguards that surpass the threshold of state and federal requirements. The accreditation program utilizes a voluntary, peer-driven review and educational model.
Through the accreditation process, organizations must demonstrate that they have built extensive safeguards into every level of their research operation and that they adhere to the highest standards for research. AAHRPP’s standards exceed federal regulations by requiring organizations to address conflicts of interest, to provide community outreach and education, and to apply the same stringent protections to all research involving human participants.
Quorum Review was initially awarded full accreditation status from AAHRPP in April of 2006. Accredited organizations are required to renew their accreditation with AAHRPP every three years to demonstrate compliance with current AAHRPP criteria.
Since the last review by AAHRPP in 2006, Quorum has made several changes to its service offerings, including reviewing studies in Canada. Because of these changes, AAHRPP applied the Canadian Tri-Council Policy Statement guidelines in addition to U.S. guidelines in reviewing Quorum’s processes. Quorum is now one of only a few AAHRPP-accredited IRBs that is specifically accredited to review studies in Canada as well as the United States.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.